Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer

About this update from Candel Therapeutics, Inc.

NEEDHAM, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced the appointment of Mark Sims as the Company's Chief Commercial Officer, effective July 6, 2026. Mr. Sims will lead Candel's commercial strategy and launch readiness for aglatimagene besadenovec (aglatimagene or CAN-2409) in intermediate- to high-risk localized prostate cancer. "The appointment of Mark Sims represents another important step in Candel's evolution toward becoming a potential commercial-stage oncology company. With positive phase 3 clinical trial data, the FDA's Regenerative Medicine Advanced Therapy designation, a planned BLA submission for aglatimagene in the fourth quarter of 2026, and preparation for a potential commercial launch already underway, we are building the capabilities required to bring aglatimagene, if approved, to patients as efficiently as possible," said Paul Peter Tak, M.D., Ph.D., FMedSci, President and Chief Executive Officer of Candel. "We believe that intermediate- to high-risk localized prostate cancer represents a large and well-defined market opportunity, with approximately 65,000 patients diagnosed annually in the United States who are candidates for radiotherapy-based treatment approaches with curative intent. Mr. Sims has led and scaled some of oncology's most significant franchises, and we believe his deep experience bringing innovative therapies to market will be instrumental to making aglatimagene, if approved, available to patients." Aglatimagene is an off-the-shelf, replication-defective adenovirus designed to induce immunogenic cell death and activate a systemic anti-tumor immune response. The Company has adopted a partnership-driven commercial model, working with EVERSANA on commercialization and IDEA Pharma on strategic positioning, designed to provide immediate access to leading commercial capabilities while maintaining the financial flexibility that has characterized Candel's approach to development. Commercial preparations are underway across market access, medical affairs, manufacturing, physician engagement, and launch planning activities. Mr. Sims will work closely with these partners as Candel prepares for a potential commercial launch of aglatimagene following its planned BLA submission in the fourth quarter of 2026.

View stock analysis, news, and events for Candel Therapeutics, Inc.